Progress on the Computational Development of Epigenetic Modulators of DNA Methyltransferases 3A and 3B
DOI:
https://doi.org/10.29356/jmcs.v61i3.353Keywords:
Drug discovery, Epi-informatics, epigenetics, DNA methyltransferase, structure-activity relationshipsAbstract
Inhibitors of DNA methyltransferases 3A and 3B (DNMT3A/3B) are promising candidates for the treatment of cancer and other diseases. Selective inhibitors of DNMT3A/3B are also attractive as small-molecule probes. During the past few years has increased significantly the research towards the development of DNMT1 inhibitors. However, there are no reviews of the recent progress in the development of small-molecule inhibitors of DNMT3A/B. Herein we review the status of inhibitors of DNMT3A/3B with emphasis on computational guided approaches. We discuss in a critical manner compound databases containing structure-activity information, crystallographic structures of DNMT3s, structure-guided studies, and virtual (in silico) screening coupled with experimental validation that have led to the identification or development of selective inhibitors. Perspectives in the field are also discussed.Downloads
Download data is not yet available.
Downloads
Published
2017-10-26
Issue
Section
Regular Articles
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
